Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company dedicated to transforming the treatment landscape for patients with serious bleeding and thrombotic disorders. The company leverages its deep expertise in blood clotting biology to develop a pipeline of first-in-class prophylactic therapies. Hemab's strategic focus is on addressing rare and underserved hematological conditions where current treatment options are limited or non-existent. The company's lead product candidate, HMB-001, is a bispecific antibody designed to bind and recruit Factor VIIa to activated platelets, specifically targeting Glanzmann Thrombasthenia, a severe rare bleeding disorder. Another key candidate in their pipeline is HMB-VWF, aimed at treating von Willebrand disease. By utilizing innovative engineering platforms, Hemab aims to provide long-acting, subcutaneous treatments that improve patient outcomes and quality of life. Founded by experts in the field of hematology and backed by prominent life science investors, Hemab operates with a dual presence in Denmark and the United States. The company is led by CEO Benny Sorensen, MD, PhD, who brings extensive experience in clinical development and hematology. Hemab's mission is to build a sustainable, fully integrated company that delivers life-changing medicines to patients globally, while advancing the science of hemostasis and thrombosis.
Book value of equity per share effectively indicates a firm's net asset value (total assets - total liabilities) on a per-share basis. References: Below 1: the company is trading below its equity. Equal to 1: the company is trading at the exact value of its equity. Above 1: The company is trading above its equity.
Shows how much the market values every dollar of the company's sales.
Shows how much the market values every dollar of the company's EBITDA.
The price-to-cash flow (P/CF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its operating cash flow per share. The ratio uses operating cash flow (OCF), which adds back non-cash expenses such as depreciation and amortization to net income. P/CF is especially useful for valuing stocks that have positive cash flow but are not profitable because of large non-cash charges.
The price-to-free cash flow (P/FCF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its free cash flow per share. This metric is very similar to the valuation metric of price to cash flow but is considered a more exact measure because it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.
The price-to-earnings ratio is the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS) and is used by investors and analysts to determine the relative value of a company's shares in an apples-to-apples comparison.
Book value per share (BVPS) takes the ratio of a firm's common equity divided by its number of shares outstanding.
Earnings per share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability. EPS indicates how much money a company makes for each share of its stock and is a widely used metric for estimating corporate value.
...and much more!